# Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis

> **NCT01962376** · PHASE4 · UNKNOWN · sponsor: **Hebei Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer
- Liver Metastasis

## Interventions

- **DRUG:** Oxaliplatin;Capecitabine
- **DRUG:** Oxaliplatin;Capecitabine;Bevacizumab

## Key facts

- **NCT ID:** NCT01962376
- **Lead sponsor:** Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-02
- **Primary completion:** 2014-12
- **Final completion:** 2015-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01962376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01962376, "Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01962376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*